Enrolling patients with tumors harboring pathogenic mutation genes other than ATM, BRCA1 and BRCA2 was challenging owing to the low prevalence of pathogenic alterations affecting these genes in patients with metastatic cancer (<1%). This evidence concerns the gene BRCA2 and metastatic malignant neoplasm.